Enprofylline protects motor neurons from in vitro excitotoxic challenge

Neurodegenerative Diseases

Volumn 2, Issue 3-4, 2006, Pages 160-165

  Mojsilovic Petrovic, Jelena ^a   Arneja, Amrita ^a   Kalb, Robert G ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Adenosine A2a receptor; Amyotrophic lateral sclerosis; Brain derived neurotrophic factor; Transactivation; Trk receptor

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; ENPROFYLLINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; EXCITOTOXICITY; IN VITRO STUDY; MOTONEURON; NERVE CELL NECROSIS; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SPINAL CORD; TISSUE CULTURE; TRANSACTIVATION;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CELLS, CULTURED; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; KAINIC ACID; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TRKB; RECEPTORS, ADENOSINE A2; XANTHINES;

EID: 33744817959     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000089621     Document Type: Article

References (51)

1. Olney JW: Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969;164:719-721.
2. Choi DW: Glutamate neurotoxicity and disease of the nervous system. Neuron 1988;1:623-634
3. Rothstein JD, Tsai G, Kuncl RW, et al: Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
4. Rothstein JD, Martin LJ, Kuncl RW: Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-1468.
5. Rothstein JD: Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995;68:7-20.
6. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S: Glutamate receptors: RNA editing and death of motor neurons. Nature 2004;427:801.
7. Vandenberghe W, Ihle EC, Patneau DK, Robberecht W, Brorson JR: AMPA receptor current density, not desensitization, predicts selective motoneuron vulnerability. J Neurosci 2000;20:7158-7166.
8. Rothstein JD, Patel S, Regan MR, et al: Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-77.
9. Durham HD, Roy J, Dong L, Figlewicz DA: Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997;56:523-530.
10. Fryer HJL, Knox RJ, Strittmatter SM, Kalb RG: Excitotoxic death of a subset of embryonic rat motor neurons in vitro. J Neurochem 1999;72:500-513.
11. Fryer HJL, Wolf DH, Knox RJ, et al: Brain-derived neurotrophic factor induces excitotoxic sensitivity in cultured embryonic rat spinal motor neurons through activation of the phosphatidylinositol 3-kinase pathway. J Neurochem 2000;74:582-595.
12. Hu P, Kalb RG: BDNF heightens the sensitivity of motor neurons to excitotoxic insults through activation of TrkB. J Neurochem 2003;84:1421-1430.
13. Cleveland DW, Rothstein JD: From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806-819.
14. Sendtner M, Thoenen H: Oxidative stress and motoneuron disease. Curr Biol 1994;4:1036-1039.
15. Bruijn LI, Miller TM, Cleveland DW: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723-749.
16. Barbeito LH, Pehar M, Cassina P, et al: A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev 2004;47:263-274.
17. Cassina P, Pehar M, Vargas MR, et al: Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem 2005;93:38-46.
18. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-591.
19. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW: Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90:6591-6595.
20. Smeyne RJ, Klein R, Schnapp A, et al: Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature 1994;368:246-249.
21. Klein R, Smeyne RJ, Wurst W, et al: Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell 1993;75:113-122.
22. Klein R, Silos-Santiago I, Smeyne RJ, et al: Disruption of the neurotrophin-3 receptor gene trkC eliminates Ia muscle afferents and results in abnormal movements. Nature 1994;368:249-251.
23. Calissano P, Ciotti MT, Battistini L, et al: Recombinant human insulin-like growth factor I exerts a trophic action and confers glutamate sensitivity on glutamate-resistant cerebellar granule cells. Proc Natl Acad Sci USA 1993;90:8752-8756.
24. 2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 1995;65:1740-1751.
25. Ellsworth JL, Garcia R, Yu J, Kindy MS: Fibroblast growth factor-18 reduced infarct volumes and behavioral deficits after transient occlusion of the middle cerebral artery in rats. Stroke 2003;34:1507-1512.
26. Leist M, Ghezzi P, Grasso G, et al: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
27. Erbayraktar S, Grasso G, Sfacteria A, et al: Asialoerythropoietin is a non-erythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003;100:6741-6746.
28. Saatman KE, Contreras PC, Smith DH, et al: Insulin-like growth factor-1 improves both neurological motor and cognitive outcome following experimental brain injury. Exp Neurol 1997;147:418-427.
29. Kalb R: The protean actions of neurotrophins and their receptors on the life and death of neurons. Trends Neurosci 2005;28:5-11.
30. Koh JY, Gwag BJ, Lobner D, Choi DW: Potentiated necrosis of cultured cortical neurons by neurotrophins. Science 1995;268:573-575.
31. Rose K, Goldberg MP, Choi DW: Cytotoxicity in murine neocortical cell culture; in Tyson CA, Frazier JM (ed): In vitro Biological Methods. Methods in Toxicology. San Diego, Academic Press, 1993, pp 46-60.
32. Lee FS, Rajagopal R, Chao MV: Distinctive features of Trk neurotrophin receptor transactivation by G-protein-coupled receptors. Cytokine Growth Factor Rev 2002;13:11-17.
33. Gotow T, Tanaka J: Phosphorylation of neurofilament H subunit as related to arrangement of neurofilaments. J Neurosci Res 1994;37:691-713.
34. Carriedo SG, Yin HZ, Weiss JH: Motor neurons are selectively vulnerable to AMPA/KA receptor-mediated injury in vitro. J Neurosci 1996;16:4069-4079.
35. 2+ overload and ROS generation in spinal motor neurons in vitro. J Neurosci 2000;20:240-250.
36. Bar-Peled O, Knudson M, Korsmeyer SJ, Rothstein JD: Motor neuron degeneration is attenuated in bax-deficient neurons in vitro. J Neurosci Res 1999;55:542-556.
37. Arundine M, Tymianski M: Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 2004;61:657-668.
38. Downward J: Role of receptor tyrosine kinases in G-protein-coupled receptor regulation of Ras: transactivation or parallel pathways? Biochem J 2003;376:e9-e10.
39. Thuringer D, Maulon L, Frelin C: Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 2002;277:2028-2032.
40. Liu J, Liao Z, Camden J, et al: Src homology 3 binding sites in the P2Y2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors. J Biol Chem 2004;279:8212-8218.
41. 2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003;373:25-32.
42. 2 receptor. Mol Endocrinol 2004;18:640-652.
43. Rajagopal R, Chen ZY, Lee FS, Chao MV: Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. J Neurosci 2004;24:6650-6658.
44. Lee FS, Chao MV: Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci USA 2001;98:3555-3560.
45. Fischer OM, Giordano S, Comoglio PM, Ullrich A: Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 2004;279:28970-28978.
46. Zhu S, Stavrovskaya IG, Drozda M, et al: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
47. 2+ exchanger in excitotoxicity. Cell 2005;120:275-285.
48. Storkebaum E, Lambrechts D, Dewerchin M, et al: Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8:85-92.
49. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH: Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301:839-842.
50. 2A receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.
51. 2A receptor selective antagonist KW6002: research and development toward a novel non-dopaminergic therapy for Parkinson's disease. Neurology 2003;61:S97-S100.